Vestcor Inc Reduces Stake in Eli Lilly and Company

Institutional investor decreases holdings in pharmaceutical giant by 11.6% in Q3

Published on Mar. 9, 2026

Vestcor Inc, an investment management firm, decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.6% during the third quarter, according to a recent SEC filing. The fund now owns 28,728 shares of the company's stock, valued at $21.9 million, making it the 29th largest holding in Vestcor's investment portfolio.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor changes in ownership of Lilly's stock, as it can signal broader market sentiment and investment trends within the healthcare sector.

The details

According to the 13F filing, Vestcor sold 3,775 shares of Eli Lilly during the third quarter, reducing its total position to 28,728 shares. The move comes as Lilly's stock price has risen significantly over the past year, reaching new all-time highs. Vestcor's holdings in Lilly now account for approximately 0.7% of its total investment portfolio.

  • Vestcor decreased its Eli Lilly stake during the third quarter of 2026.

The players

Vestcor Inc

An investment management firm that owns a portfolio of stocks, including shares in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Vestcor's Eli Lilly holdings, while relatively small, could signal a broader shift in investor sentiment around the stock as it has reached new highs. However, Lilly remains a core holding for the firm, underscoring the company's continued importance in the pharmaceutical landscape.